Needham Maintains Buy on Hims & Hers Health, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

Needham analyst Ryan MacDonald maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $35 to $42.